BAYESIAN APPROACH TO NONINFERIORITY TRIALS FOR PROPORTIONS

被引:22
作者
Gamalo, Mark A. [1 ]
Wu, Rui [2 ]
Tiwari, Ram C. [1 ]
机构
[1] US FDA, Off Biostat, Silver Spring, MD 20993 USA
[2] Univ Connecticut, Dept Stat, Storrs, CT 06269 USA
关键词
Bayesian criterion; Bayesian paradigm; Beta-binomial; Noninferiority margin; Normal approximation; STATISTICAL-METHODS; PLACEBO; ISSUES;
D O I
10.1080/10543406.2011.589646
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Noninferiority trials are unique because they are dependent upon historical information in order to make meaningful interpretation of their results. Hence, a direct application of the Bayesian paradigm in sequential learning becomes apparently useful in the analysis. This paper describes a Bayesian procedure for testing noninferiority in two-arm studies with a binary primary endpoint that allows the incorporation of historical data on an active control via the use of informative priors. In particular, the posteriors of the response in historical trials are assumed as priors for its corresponding parameters in the current trial, where that treatment serves as the active control. The Bayesian procedure includes a fully Bayesian method and two normal approximation methods on the prior and/or on the posterior distributions. Then a common Bayesian decision criterion is used but with two prespecified cutoff levels, one for the approximation methods and the other for the fully Bayesian method, to determine whether the experimental treatment is noninferior to the active control. This criterion is evaluated and compared with the frequentist method using simulation studies in keeping with regulatory framework that new methods must protect type I error and arrive at a similar conclusion with existing standard strategies. Results show that both methods arrive at comparable conclusions of noninferiority when applied to a modified real data set. The advantage of the proposed Bayesian approach lies in its ability to provide posterior probabilities for effect sizes of the experimental treatment over the active control.
引用
收藏
页码:902 / 919
页数:18
相关论文
共 50 条
  • [31] Avoiding ambiguity with the Type I error rate in noninferiority trials
    Kang, Seung-Ho
    JOURNAL OF BIOPHARMACEUTICAL STATISTICS, 2016, 26 (03) : 452 - 465
  • [32] The utility of active-controlled noninferiority/equivalence trials in drug development
    Tsong Y.
    International Journal of Pharmaceutical Medicine, 2007, 21 (3) : 225 - 233
  • [33] Reporting of Noninferiority and Equivalence Randomized Trials Extension of the CONSORT 2010 Statement
    Piaggio, Gilda
    Elbourne, Diana R.
    Pocock, Stuart J.
    Evans, Stephen J. W.
    Altman, Douglas G.
    JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2012, 308 (24): : 2594 - 2604
  • [34] Noninferiority and Equivalence Tests in Sequential, Multiple Assignment, Randomized Trials (SMARTs)
    Ghosh, Palash
    Nahum-Shani, Inbal
    Spring, Bonnie
    Chakraborty, Bibhas
    PSYCHOLOGICAL METHODS, 2020, 25 (02) : 182 - 205
  • [35] Bayesian clinical trials in action
    Lee, J. Jack
    Chu, Caleb T.
    STATISTICS IN MEDICINE, 2012, 31 (25) : 2955 - 2972
  • [36] The Adjustment of the Type I Error Rate in Noninferiority Trials with -Margin Approach: Each of Two Different New Drugs is Approved with Two Independent Trials with the Same Active Control
    Kang, Seung-Ho
    Ryu, Yuman
    JOURNAL OF BIOPHARMACEUTICAL STATISTICS, 2011, 21 (03) : 498 - 510
  • [37] Sample size for comparing negative binomial rates in noninferiority and equivalence trials with unequal follow-up times
    Tang, Yongqiang
    JOURNAL OF BIOPHARMACEUTICAL STATISTICS, 2018, 28 (03) : 475 - 491
  • [38] A generalized p-value approach for assessing noninferiority in a three-arm trial
    Gamalo, Mark A.
    Muthukumarana, Saman
    Ghosh, Pulak
    Tiwari, Ram C.
    STATISTICAL METHODS IN MEDICAL RESEARCH, 2013, 22 (03) : 261 - 277
  • [39] Strength of Evidence of Noninferiority Trials with the Two Confidence Interval Method with Random Margin
    Wang, So-Young
    Kang, Seung-Ho
    JOURNAL OF BIOPHARMACEUTICAL STATISTICS, 2013, 23 (02) : 307 - 321
  • [40] Most noninferiority trials were not designed to preserve active comparator treatment effects
    Tsui, Michael
    Rehal, Sunita
    Jairath, Vipul
    Kahan, Brennan C.
    JOURNAL OF CLINICAL EPIDEMIOLOGY, 2019, 110 : 82 - 89